Last reviewed: June 1, 2026
2009Nature Genetics
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al.
Abstract summary
One of the first large-scale GWAS studies to discover new Alzheimer's disease susceptibility loci beyond APOE. Identified CLU (clusterin) and CR1 (complement receptor 1) as genome-wide significant AD risk genes, implicating lipid metabolism and complement pathways in AD pathogenesis. Companion study to Lambert et al. 2009.
Evidence labels
human genetics
Therapeutic relevance
Established complement biology and lipid metabolism as genetic risk pathways in AD, supporting complement-targeted therapeutic approaches.
Last reviewed: June 1, 2026